Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients ≥ 18 years of age.
Written informed consent.
Recurrent or metastatic, Stage III or IV non-small cell lung cancer (NSCLC).
Measurable disease (Response Evaluation Criteria In Solid Tumors).
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Prior course of standard systemic chemotherapy.
You may not be if
\- Contra-indications to treatment with Tarceva.
Clareo Health | An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
